On
The MAIDAM project is focused on developing AI-based approaches for the monitoring and improvement of decentralized manufacturing processes for ATMPs via federated machine and reinforcement learning utilizing cell therapy processing on small and standardized manufacturing units. The project is intended to address the challenges of decentralization by developing innovative digital tools allowing providers to be more competitive by leveraging data from local production units.
Orgenesis Services Belgium General Manager
“OMPULs are multi-purpose, mobile, autonomous facilities that can be rapidly deployed as a standardized industrial cleanroom alternative, at or near the point of care. Through this grant, we plan to utilize cutting-edge single cell bioinformatics research to identify cells of the highest quality and develop a database that will be the basis for AI software to better select cells that meet clinical standards. Through these steps, we are clearly executing on our strategy to make cell and gene therapies more accessible and affordable for patients.”
Thibault Helleputte, CEO of DNAlytics stated: “I believe that the MAIDAM project will allow the
About
About DNAlytics
DNAlytics is a Belgian company providing data sciences expertise to the healthcare industry exclusively. It has served about fifty customers over a hundred of projects over the last decade. It supports biotech, pharma, medtech and academia R&D teams, manufacturing departments, and is also active in real-world medical data interoperability. Regarding biomanufacturing, the company develops and markets its Hercule software suite, bringing valuable data models, statistical routines, as well as machine learning and AI functionalities to develop and improve biomanufacturing process. Hercule has been applied to more than 25 processes so far, half of which are commercial-stage processes. http://dnalytics.com/Hercule .
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the expected consolidation of Octomera in our consolidated financial statements, our reliance on, and our ability to grow, our decentralized cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our decentralized cell therapy processing, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended
Investor relations contact for
Tel: 212-671-1021
Orgs@crescendo-ir.com
Communications contact for
Source:
2024 GlobeNewswire, Inc., source